Loading...

We've got a brand new version of Simply Wall St! Try it out

Imugene

ASX:IMU
Snowflake Description

Flawless balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
IMU
ASX
A$163M
Market Cap
  1. Home
  2. AU
  3. Pharmaceuticals & Biotech
Company description

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. The last earnings update was 80 days ago. More info.


Add to Portfolio Compare Print
  • Imugene has significant price volatility in the past 3 months.
IMU Share Price and Events
7 Day Returns
60.6%
ASX:IMU
4.7%
AU Biotechs
0.9%
AU Market
1 Year Returns
140.9%
ASX:IMU
50.9%
AU Biotechs
16.3%
AU Market
IMU Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Imugene (IMU) 60.6% 152.4% 165% 140.9% 489% 381.9%
AU Biotechs 4.7% 8.7% 20% 50.9% 168.8% 226.4%
AU Market 0.9% 1.9% 5.1% 16.3% 22.3% 22.5%
1 Year Return vs Industry and Market
  • IMU outperformed the Biotechs industry which returned 50.9% over the past year.
  • IMU outperformed the Market in Australia which returned 16.3% over the past year.
Price Volatility
IMU
Industry
5yr Volatility vs Market

Value

 Is Imugene undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Imugene. This is due to cash flow or dividend data being unavailable. The share price is A$0.053.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Imugene's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Imugene's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:IMU PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in AUD A$0.00
ASX:IMU Share Price ** ASX (2019-11-18) in AUD A$0.05
Global Biotechs Industry PE Ratio Median Figure of 145 Publicly-Listed Biotechs Companies 30.8x
Australia Market PE Ratio Median Figure of 519 Publicly-Listed Companies 18.63x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Imugene.

ASX:IMU PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:IMU Share Price ÷ EPS (both in AUD)

= 0.05 ÷ 0.00

-24.42x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Imugene is loss making, we can't compare its value to the Global Biotechs industry average.
  • Imugene is loss making, we can't compare the value of its earnings to the Australia market.
Price based on expected Growth
Does Imugene's expected growth come at a high price?
Raw Data
ASX:IMU PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -24.42x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
Not available
Global Biotechs Industry PEG Ratio Median Figure of 85 Publicly-Listed Biotechs Companies 1.39x
Australia Market PEG Ratio Median Figure of 347 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Imugene, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Imugene's assets?
Raw Data
ASX:IMU PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in AUD A$0.01
ASX:IMU Share Price * ASX (2019-11-18) in AUD A$0.05
Australia Biotechs Industry PB Ratio Median Figure of 38 Publicly-Listed Biotechs Companies 3.17x
Australia Market PB Ratio Median Figure of 1,584 Publicly-Listed Companies 1.75x
ASX:IMU PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:IMU Share Price ÷ Book Value per Share (both in AUD)

= 0.05 ÷ 0.01

7.01x

* Primary Listing of Imugene.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Imugene is overvalued based on assets compared to the AU Biotechs industry average.
X
Value checks
We assess Imugene's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Imugene has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Imugene expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
13%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Imugene expected to grow at an attractive rate?
  • Unable to compare Imugene's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Imugene's earnings growth to the Australia market average as no estimate data is available.
  • Unable to compare Imugene's revenue growth to the Australia market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
ASX:IMU Future Growth Rates Data Sources
Data Point Source Value (per year)
Australia Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 13%
Australia Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 10.3%
Australia Market Earnings Growth Rate Market Cap Weighted Average 9.7%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3.7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:IMU Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:IMU Future Estimates Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-06-30 3 -8 1
ASX:IMU Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2019-06-30 4 -8 -8
2019-03-31 3 -7 -7
2018-12-31 3 -6 -6
2018-09-30 2 -5 -5
2018-06-30 2 -5 -4
2018-03-31 1 -4 -3
2017-12-31 1 -3 -3
2017-09-30 1 -3 -3
2017-06-30 1 -3 -3
2017-03-31 1 -3 -3
2016-12-31 2 -3 -3
2016-09-30 2 -3 -3

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Imugene is high growth as no earnings estimate data is available.
  • Unable to determine if Imugene is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:IMU Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Imugene Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:IMU Future Estimates Data
Date (Data in AUD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-06-30 0.00 0.00 0.00 1.00
ASX:IMU Past Financials Data
Date (Data in AUD Millions) EPS *
2019-06-30 0.00
2019-03-31 0.00
2018-12-31 0.00
2018-09-30 0.00
2018-06-30 0.00
2018-03-31 0.00
2017-12-31 0.00
2017-09-30 0.00
2017-06-30 0.00
2017-03-31 0.00
2016-12-31 0.00
2016-09-30 0.00

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Imugene will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Imugene's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Imugene has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Imugene performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Imugene's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Imugene does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Imugene's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Imugene's 1-year growth to the Global Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Imugene's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Imugene Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:IMU Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 4.13 -7.78 4.78 7.61
2019-03-31 3.45 -6.76 4.05 6.52
2018-12-31 2.77 -5.75 2.41 6.35
2018-09-30 2.30 -4.84 2.02 5.25
2018-06-30 1.84 -3.93 2.55 3.22
2018-03-31 1.47 -3.29 1.91 2.87
2017-12-31 1.09 -2.65 1.26 2.51
2017-09-30 1.13 -2.58 1.24 2.49
2017-06-30 1.16 -2.51 1.21 2.47
2017-03-31 1.43 -2.85 1.36 2.88
2016-12-31 1.70 -3.19 1.52 3.30
2016-09-30 1.63 -2.96 1.54 3.00
2016-06-30 1.56 -2.73 1.57 2.70
2016-03-31 1.18 -2.58 1.41 2.28
2015-12-31 0.79 -2.42 1.24 1.86
2015-09-30 0.72 -2.43 1.23 1.77
2015-06-30 0.64 -2.44 1.22 1.67
2015-03-31 0.83 -2.05 1.16 1.43
2014-12-31 1.01 -1.65 1.09 1.19
2014-09-30 0.78 -1.89 0.98 0.83
2014-06-30 0.54 -2.12 0.87 0.47
2014-03-31 0.37 -1.98 0.90 0.30
2013-12-31 0.20 -1.84 0.93 0.13
2013-09-30 0.20 -1.70 1.03 0.37
2013-06-30 0.21 -1.56 1.14 0.60
2013-03-31 0.14 -1.62 1.06 0.65
2012-12-31 0.07 -1.69 0.98 0.69

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Imugene has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Imugene has efficiently used its assets last year compared to the Global Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Imugene improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Imugene's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Imugene has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Imugene's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Imugene's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Imugene is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Imugene's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Imugene's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Imugene has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Imugene Company Filings, last reported 4 months ago.

ASX:IMU Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 27.29 0.00 19.05
2019-03-31 27.29 0.00 19.05
2018-12-31 31.19 0.00 24.05
2018-09-30 31.19 0.00 24.05
2018-06-30 15.48 0.00 7.82
2018-03-31 15.48 0.00 7.82
2017-12-31 17.84 0.00 11.92
2017-09-30 17.84 0.00 11.92
2017-06-30 11.39 0.00 4.81
2017-03-31 11.39 0.00 4.81
2016-12-31 9.38 0.00 3.83
2016-09-30 9.38 0.00 3.83
2016-06-30 7.86 0.00 1.58
2016-03-31 7.86 0.00 1.58
2015-12-31 9.49 0.00 3.72
2015-09-30 9.49 0.00 3.72
2015-06-30 7.73 0.00 1.96
2015-03-31 7.73 0.00 1.96
2014-12-31 9.16 0.00 2.99
2014-09-30 9.16 0.00 2.99
2014-06-30 6.73 0.00 1.22
2014-03-31 6.73 0.00 1.22
2013-12-31 7.34 0.00 2.46
2013-09-30 7.34 0.00 2.46
2013-06-30 1.89 0.00 0.57
2013-03-31 1.89 0.00 0.57
2012-12-31 2.05 0.01 0.75
  • Imugene has no debt.
  • Imugene currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Imugene has sufficient cash runway for 2.4 years based on current free cash flow.
  • Imugene has sufficient cash runway for 1.6 years if free cash flow continues to grow at historical rates of 41.4% each year.
X
Financial health checks
We assess Imugene's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Imugene has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Imugene's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Imugene dividends.
If you bought A$2,000 of Imugene shares you are expected to receive A$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Imugene's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Imugene's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:IMU Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 59 Stocks 2.1%
Australia Market Average Dividend Yield Market Cap Weighted Average of 390 Stocks 4%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.5%
Australia Bottom 25% Dividend Yield 25th Percentile 2.4%
Australia Top 25% Dividend Yield 75th Percentile 5.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

ASX:IMU Future Dividends Estimate Data
Date (Data in A$) Dividend per Share (annual) Avg. No. Analysts
2020-06-30

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Imugene has not reported any payouts.
  • Unable to verify if Imugene's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Imugene's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Imugene has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Imugene's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.5%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Imugene afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Imugene has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Imugene's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Leslie Chong
COMPENSATION A$777,224
TENURE AS CEO 3 years
CEO Bio

Ms. Leslie Chong has been the Chief Executive Officer of Imugene Ltd. since November 21, 2016 and its Managing Director since March 28, 2018. She is an Executive Director of Imugene Limited. Ms. Chong serves as a Member of the Clinical Operation Department at GSK and PPD. She served as Chief Operating Officer of Imugene Ltd. since August 27, 2015 until November 21, 2016. She served as Senior Clinical Program Lead at Genentech. Most recently, she served as the Clinical Operations Program Lead for the approved MEK inhibitor in cell-signalling targeted therapy, cobimetinib/Cotellic. Prior to Genentech, Ms. Chong was one of the Clinical Operation Head at Exelixis, in development of 14 compounds and molecules. She has over 17 years of experience in leading clinical and department development in oncology.

CEO Compensation
  • Leslie's compensation has increased whilst company is loss making.
  • Leslie's remuneration is higher than average for companies of similar size in Australia.
Management Team Tenure

Average tenure and age of the Imugene management team in years:

5
Average Tenure
60
Average Age
  • The tenure for the Imugene management team is about average.
Management Team

Paul Hopper

TITLE
Executive Chairman
COMPENSATION
A$422K
AGE
63

Leslie Chong

TITLE
CEO, MD & Executive Director
COMPENSATION
A$777K
TENURE
3 yrs

Nick Ede

TITLE
Chief Technology Officer
COMPENSATION
A$442K

Mark Marino

TITLE
Chief Medical Officer
COMPENSATION
A$362K
AGE
59
TENURE
1.3 yrs

Phillip Hains

TITLE
CFO & Joint Company Secretary
COMPENSATION
A$73K
AGE
60
TENURE
6.9 yrs

Justyn Stedwell

TITLE
Joint Company Secretary
COMPENSATION
A$12K
TENURE
7.3 yrs
Board of Directors Tenure

Average tenure of the Imugene board of directors in years:

2.8
Average Tenure
  • The average tenure for the Imugene board of directors is less than 3 years, this suggests a new board.
Board of Directors

Leslie Chong

TITLE
CEO, MD & Executive Director
COMPENSATION
A$777K
TENURE
1.7 yrs

Axel Hoos

TITLE
Non-Executive Director
COMPENSATION
A$124K
TENURE
5.9 yrs

Paul Hopper

TITLE
Executive Chairman
COMPENSATION
A$422K
AGE
63

Charlie Walker

TITLE
Non-Executive Director
COMPENSATION
A$127K
TENURE
4.2 yrs

Neil Segal

TITLE
Member of Scientific Advisory Board
TENURE
5.6 yrs

Ursula Wiedermann

TITLE
Member of Scientific Advisory Board

Yelena Janjigian

TITLE
Scientific Advisory Board Member
TENURE
3.6 yrs

Peter Schmid

TITLE
Member of Scientific Advisory Board
TENURE
1.9 yrs

Tanios Bekaii-Saab

TITLE
Member of Scientific Advisory Board
TENURE
1.2 yrs

Pravin T. Kaumaya

TITLE
Member of Scientific Advisory Board
TENURE
1.1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
20. Dec 18 Buy Paul Hopper Individual 19. Dec 18 19. Dec 18 500,000 A$0.02 A$10,000
X
Management checks
We assess Imugene's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Imugene has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Does Imugene Limited's (ASX:IMU) CEO Salary Reflect Performance?

This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … See our latest analysis for Imugene How Does Leslie Chong's Compensation Compare With Similar Sized Companies? … I think that the total shareholder return of 72%, over three years, would leave most Imugene Limited shareholders smiling.

Simply Wall St -

Investors Who Bought Imugene (ASX:IMU) Shares Three Years Ago Are Now Up 55%

While Imugene Limited (ASX:IMU) shareholders are probably generally happy, the stock hasn't had particularly good run recently, with the share price falling 15% in the last quarter. … In the last three years the share price is up, 55%: better than the market. … And with the share price up 16% per year, over 3 years, the market is focussed on that blue sky potential

Simply Wall St -

What Investors Should Know About Imugene Limited's (ASX:IMU) Financial Strength

However, it also faces higher cost of capital given interest cost is generally lower than equity. … Is IMU growing fast enough to value financial flexibility over lower cost of capital. … Debt capital generally has lower cost of capital compared to equity funding

Simply Wall St -

What Percentage Of Imugene Limited (ASX:IMU) Shares Do Insiders Own?

If you want to know who really controls Imugene Limited (ASX:IMU), then you'll have to look at the makeup of its share registry. … With a market capitalization of AU$69m, Imugene is a small cap stock, so it might not be well known by many institutional investors. … View our latest analysis for Imugene

Simply Wall St -

Is Imugene Limited's (ASX:IMU) Balance Sheet A Threat To Its Future?

However, the trade-off is IMU will have to adhere to stricter debt covenants and have less financial flexibility. … Does IMU's growth rate justify its decision for financial flexibility over lower cost of capital. … There are well-known benefits of including debt in capital structure, primarily a lower cost of capital

Simply Wall St -

What You Must Know About Imugene Limited's (ASX:IMU) Financial Strength

However, it also faces higher cost of capital given interest cost is generally lower than equity. … Is IMU right in choosing financial flexibility over lower cost of capital … There are well-known benefits of including debt in capital structure, primarily a lower cost of capital.

Simply Wall St -

Company Info

Description

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company’s HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and B-Vaxx, a cancer vaccine to treat tumors that over-express the HER2/neu receptor. Imugene Limited was incorporated in 1986 and is headquartered in Sydney, Australia.

Details
Name: Imugene Limited
IMU
Exchange: ASX
Founded: 1986
A$162,668,170
3,614,848,240
Website: http://www.imugene.com
Address: Imugene Limited
37 Bligh Street,
Suite 1006,
Sydney,
New South Wales, 2000,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX IMU Ordinary Shares Australian Securities Exchange AU AUD 02. Sep 2002
OTCPK IUGN.F Ordinary Shares Pink Sheets LLC US USD 02. Sep 2002
CHIA IMU Ordinary Shares Chi-X Australia AU AUD 02. Sep 2002
Number of employees
Current staff
Staff numbers
0
Imugene employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/18 10:31
End of day share price update: 2019/11/18 00:00
Last estimates confirmation: 2019/08/30
Last earnings filing: 2019/08/30
Last earnings reported: 2019/06/30
Last annual earnings reported: 2019/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.